The prognostic value of Ki67 in ovarian high-grade serous carcinoma: an 11-year cohort study of Chinese patients

Chen, Ming; Yao, Shuzhong; Cao, Qinghua; Xia, Meng; Liu, Junxiu; He, Mian

doi:10.18632/oncotarget.14112

Cited by 36 publications

(37 citation statements)

References 34 publications

(31 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…12,40,41 In our study, the Ki67 expression was significantly higher in HGSOC than in LGSOC. In agreement with Chen et al, 40 Feng et al, 12 and Bachmayr-Heyda et al, 41 we observed no relationship among Ki67 expression, stage, residual disease, recurrence, or disease progression. Some studies suggest that high expression of Ki67 is associated with worse survival because Ki67-positive tumors are highly proliferative.…”

Section: Discussionsupporting

confidence: 49%

BRCA1, Ki67, and β-Catenin Immunoexpression Is Not Related to Differentiation, Platinum Response, or Prognosis in Women With Low- and High-Grade Serous Ovarian Carcinoma

Sallum¹,

Andrade²,

Costa³

et al. 2018

Int J Gynecol Cancer

View full text Add to dashboard Cite

Ki67 expression was significantly higher in HGSOC. BRCA1 and β-catenin expression did not differ between LGSOC and HGSOC samples. BRCA1, Ki67, and β-catenin expression was neither related to clinicopathological features, response to platinum-based chemotherapy, nor survival. Only International Federation of Gynecology and Obstetrics stage remained associated with poor survival in women with HGSOC.

show abstract

Section: Discussionsupporting

confidence: 49%

BRCA1, Ki67, and β-Catenin Immunoexpression Is Not Related to Differentiation, Platinum Response, or Prognosis in Women With Low- and High-Grade Serous Ovarian Carcinoma

Sallum¹,

Andrade²,

Costa³

et al. 2018

Int J Gynecol Cancer

View full text Add to dashboard Cite

show abstract

“…Epithelial ovarian cancer is the most common type of ovarian cancer, which has the highest mortality rate of all gynecological malignancies. This high mortality rate is largely due to the lack of an effective biomarker; in addition, it is difficult to diagnose patients at the early stage of the disease and most patients are diagnosed at advanced stages (2)(3)(4).…”

Section: Introductionmentioning

confidence: 99%

Blocking the Nav1.5 channel using eicosapentaenoic acid reduces migration and proliferation of ovarian cancer cells

Liu

et al. 2018

Int J Oncol

Self Cite

View full text Add to dashboard Cite

Activity of the voltage-gated Nav1.5 sodium channel has been reported to be involved in cell proliferation, cancer invasion and gene expression. In addition, eicosapentaenoic acid (EPA) has recently been suggested to inhibit ovarian cancer cell growth and suppress tumor metastasis. The present study aimed to explore the association between EPA, the Nav1.5 sodium channel and ovarian cancer cells. Using patch-clamp technique and RNA interference approaches, sodium currents were recorded in epithelial ovarian cancer cells, and it was confirmed that the Nav1.5 channel carried the sodium currents. Furthermore, EPA effectively inhibited sodium currents in a dose-dependent manner, shifted the steady-state inactivation curve of sodium currents to the hyperpolarizing direction and reduced sodium window currents. In addition, EPA induced a shift in the inactivation curve in a dose-dependent manner. Inhibition of the sodium channel, either by EPA or by Nav1.5 knockdown, attenuated ovarian cancer cell migration and proliferation. To the best of our knowledge, the present study is the first to conduct sodium current recording in ovarian cancer cells, and revealed that EPA may inhibit Nav1.5-mediated ovarian cancer cell migration and growth. These findings not only present a potential prognostic biomarker for ovarian cancer, but also provide a strategy towards the development of novel pharmacological treatments for patients with ovarian cancer.

show abstract

“…Literature review revealed that there were some reports on the survival prediction model of patients with EOC [6][7][8][9][10], while the recurrence prediction model of patients with EOC is relatively less [11]. In this study, the in uencing factors related to the recurrence of EOC were screened out and evaluated by mathematical methods.…”

Section: Discussionmentioning

confidence: 99%

Establishment and verification of the nomogram that predicts the 3-year recurrence risk of epithelial ovarian carcinoma

Jiao

Zhu

et al. 2020

Preprint

View full text Add to dashboard Cite

Background As we all know, patients with epithelial ovarian carcinoma have poor prognosis and high recurrence rate. It is critical and challenging to screen out the patients with high risk of recurrence. At present, there are some models predicting the overall survival of epithelial ovarian carcinoma, however, there is no widely accepted tool or applicable model predicting the recurrence risk of epithelial ovarian carcinoma patients. The objective of this study was to establish and verify a nomogram to predict the recurrence risk of EOC.Methods We reviewed the clinicopathological and prognostic data of 193 patients with EOC who achieved clinical complete remission after cytoreductive surgery and chemotherapy between January 2003 and December 2013 in Peking University First Hospital. The nomogram was established with the risk factors selected by LASSO regression. The medical data of 187 EOC patients with 5-year standard follow-up in Peking University Third Hospital and Beijing Obstetrics and Gynecology Hospital were used for external validation of the nomogram. AUC curve and Hosmer-Lemeshow test were used to evaluate the discrimination and calibration.Results The nomogram for 3-year recurrence risk was established with FIGO stage, histological grade, histological type, lymph node metastasis status and serum CA125 level at diagnosis. The total score can be obtained by adding the grading values of these factors together. The C statistics was 0.828 [95% CI, 0.764-0.884] and the Chi-square value is 3.6 (P=0.731>0.05) with the training group. When the threshold value was set at 198, the sensitivity, specificity, positive predictive value, negative predictive value and concordance index were 88.8%, 67.0%, 71.8%, 86.3% and 0.558 respectively. In the external validation, the C statistics was 0.803 [95%CI, 0.738-0.867] and the Chi-square value is 11.04 (P=0.135>0.05). With the threshold value of 198, the sensitivity, specificity, positive predictive value, negative predictive value and concordance index of the nomogram were 75.7%, 77.0%, 83.2%, 67.9%, and 0.52 respectively.Conclusions We established and validated a nomogram to predict 3-year recurrence risk of patients with EOC who achieved clinical complete remission after cytoreductive surgery and chemotherapy. This nomogram with good discrimination and calibration might be useful for screening out the patients with high risk of recurrence.

show abstract

The prognostic value of Ki67 in ovarian high-grade serous carcinoma: an 11-year cohort study of Chinese patients

Cited by 36 publications

References 34 publications

BRCA1, Ki67, and β-Catenin Immunoexpression Is Not Related to Differentiation, Platinum Response, or Prognosis in Women With Low- and High-Grade Serous Ovarian Carcinoma

BRCA1, Ki67, and β-Catenin Immunoexpression Is Not Related to Differentiation, Platinum Response, or Prognosis in Women With Low- and High-Grade Serous Ovarian Carcinoma

Blocking the Nav1.5 channel using eicosapentaenoic acid reduces migration and proliferation of ovarian cancer cells

Establishment and verification of the nomogram that predicts the 3-year recurrence risk of epithelial ovarian carcinoma

Contact Info

Product

Resources

About